"Like other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively."@en . "Take without regard to meals."@en . . . . . . . . "30%"@en . . . . . "Used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension."@en . . . . . . . . . . "Corgard"@en . . . "Avoid alcohol."@en . . . . . . . . . . . "14-24 hours"@en . . . . . . . . "Oral, mouse: LD₅₀ = 4500mg/kg. Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing."@en . "Unlike many other beta-adrenergic blocking agents, nadolol is not metabolized by the liver and is excreted unchanged, principally by the kidneys. Nadolol is excreted predominantly in the urine."@en . . "A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem]"@en . . . . . . "Humans and other mammals"@en . "42200-33-9"@en . . . . . . . . . . . . "Magnesium, potassium and zinc needs increased."@en . . . . . . . . . . . . . . . . . . "Avoid natural licorice."@en . . . . . . . "\"DrugSyn.org\":http://www.drugsyn.org/Nadolol.htm"@en . "Nadolol"@en . . . "approved"@en . . . . . . . . . . . . . . . . "Absorption of nadolol after oral dosing is variable, averaging about 30 percent."@en . . .